Release Date: December 10, 2022
Expiration Date: February 1, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward medical oncologists, hematologic oncologists, hematologists, hematopathologists, nurses, and other healthcare professionals involved in the treatment of ALL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Utilize cytogenetic and immunophenotype characteristics to create individualized treatment strategies for adults and pediatric patients with ALL
- Assess the current and emerging role of MRD assessment in determining prognosis and in planning treatment in patients with ALL
- Evaluate the efficacy and safety of current and emerging therapies including monoclonal antibodies, ADCs as well as CAR T-cell therapies in the management of patients with ALL
- Place updated clinical trial data and evidence-based recommendations in the context of evolving management strategies utilizing antibody-based therapy in ALL management

Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AbbVie, Adaptive Biotechnologies Corp, Amgen, Inc, Bristol Myers Squibb, Novartis Pharmaceuticals Corp, Pfizer Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceutical Company Limited

Sabina Chiaretti, MD, PhD
Associate Professor
Department of Translational and Precision Medicine
Sapienza University
Rome, Italy
Disclosures: Other: (Advisory Board): AbbVie, Amgen, Inc, Gilead Sciences, Inc, Incyte

Hagop M. Kantarjian, MD
Professor and Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AbbVie, Agios Pharmaceuticals Inc, Amgen, Inc, ARIAD Pharmaceuticals Inc, Astex Pharmaceuticals Inc, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Daiichi Sankyo Inc, Immunogen Inc, Jazz Pharmaceuticals Inc, Novartis Pharmaceuticals Corp, Pfizer Inc; Other (Honoraria): AbbVie, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Amgen Inc, Immunogen Inc, Pfizer Inc, Takeda Pharmaceutical Company Limited

Rob Pieters, MD, PhD
Chief Medical Officer
Princess Máxima Center for Pediatric Oncology
Professor of Pediatric Oncology
University of Utrecht
Utrecht, Netherlands
Disclosures: Grant/Research Support: Amgen Inc, Celgene Corp, Pfizer Inc, Servier Pharmaceuticals LLC; Consultant: Erytech Pharma Inc, Jazz Pharmaceuticals Inc, Novartis Pharmaceuticals Corp, Servier Pharmaceuticals LLC; Speakers’ Bureau: Amgen Inc, Jazz Pharmaceuticals Inc, Servier Pharmaceuticals LLC

Bijal Shah, MD, MS
Associate Member, Department of Malignant Hematology
offitt Cancer Center
Tampa, FL
Disclosures: Grant/Research Support: Jazz Pharmaceuticals Inc, Kite/Gilead Sciences Inc, Servier Pharmaceuticals LLC; Consultant: Acrotech Biopharma Inc, Adaptive Biotechnologies Corporation, Amgen Inc, AstraZeneca, Autolus Therapeutics plc, BeiGene, Bristol Myers Squibb/Celgene Corp, Kite/Gilead Sciences Inc, Novartis Pharmaceuticals Corp, Precision BioSciences Inc, Pfizer Inc, Pharmacyclics LLC
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here


